BioSpace News Archive

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it will release top-line data from its Phase IIa trial of SPL026 in Major Depressive Disorder (“MDD”) prior to market-open tomorrow on Wednesday, January 25, 2023.

Pacific Biosciences of California, Inc. announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced the closing of its underwritten public offering of 7,986,111 shares of its common stock.

Acasti Pharma Inc. announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.

Basilea Pharmaceutica Ltd announced that on an unaudited preliminary basis it expects to have achieved an operating profit of approximately CHF 18 million for the financial year 2022 and expects to report a net profit.

The Japan Prize Foundation announced the winners of the 2023 Japan Prize on January 24, 2023.

BriaCell Therapeutics today issues a letter to shareholders from Dr. William V. Williams, BriaCell’s President and CEO.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023.

Beacon Biosignals CEO and co-founder Jacob Donoghue, MD, Ph.D., will be speaking at the Precision Medicine World Conference (PMWC) 2023 being held in Silicon Valley from Jan. 25-27, the company announced today.

EndoSound®, Inc., an Oregon-based medical device innovator developing technologies that enhance access, reduce cost, and increase the safety of endoscopic ultrasound (EUS) procedures, announced that the company received an investment from the American Gastroenterological Association (AGA), AGA’s new venture capital fund, GI Opportunity Fund 1.